A review of pulmonary coagulopathy in acute lung injury, acute respiratory distress syndrome and pneumonia

European Journal of Haematology

Volumn 82, Issue 6, 2009, Pages 413-425

  Nieuwenhuizen, Laurens ^a   De Groot, Philip G ^b   Grutters, Jan C ^a   Biesma, Douwe H ^b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Coagulation; Inflammation; Pneumonia

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTIINFLAMMATORY AGENT; ANTITHROMBIN; BLEOMYCIN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9A; CAPTOPRIL; CYTOKINE; DROTRECOGIN; HEPARIN; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; LOSARTAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; RECOMBINANT ANTITHROMBIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; TM 5007; UNCLASSIFIED DRUG; UROKINASE;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANTICOAGULANT THERAPY; ANTIINFLAMMATORY ACTIVITY; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CYTOKINE PRODUCTION; DRUG INHIBITION; FIBRINOLYSIS; HUMAN; HYPOXEMIA; LUNG DISEASE; LUNG FIBROSIS; LUNG INJURY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PSEUDOMONAS PNEUMONIA; PULMONARY COAGULOPATHY; RESPIRATORY FAILURE; REVIEW; STREPTOCOCCUS PNEUMONIA; TREATMENT RESPONSE;

ACUTE LUNG INJURY; HUMANS; PNEUMONIA; PULMONARY CIRCULATION; RESPIRATORY DISTRESS SYNDROME, ADULT; THROMBOPHILIA;

EID: 65349098917     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01238.x     Document Type: Review

References (156)

1. Hofstra JJ, Haitsma JJ, Juffermans NP, Levi M, Schultz MJ. The role of bronchoalveolar hemostasis in the pathogenesis of acute lung injury. Semin Thromb Hemost 2008 34 : 475 84.
2. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia - a review. Crit Care Med 2006 34 : 871 7.
3. Ware LB, Camerer E, Welty-Wolf K, Schultz MJ, Matthay MA. Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2006 291 : L307 11.
4. Biemond BJ, Levi M, ten Cate H, et al. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb Haemost 1995 73 : 223 30.
5. Levi M, ten Cate H, Bauer KA, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994 93 : 114 20.
6. van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990 76 : 2520 6.
7. ten Cate H, Bauer KA, Levi M, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993 92 : 1207 12.
8. Franco RF, de Jong E, Dekkers PE, et al. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood 2000 96 : 554 9.
9. Mann KG, van't Veer C, Cawthern K, Butenas S. The role of the tissue factor pathway in initiation of coagulation. Blood Coagul Fibrinolysis 1998 9 (Suppl. 1 S3 7.
10. Camerer E, Kolsto AB, Prydz H. Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 1996 81 : 1 41.
11. Osterud B, Bajaj MS, Bajaj SP. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. On behalf of the Subcommittee on Tissue factor Pathway Inhibitor (TFPI) of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995 73 : 873 5.
12. Saadi S, Holzknecht RA, Patte CP, Stern DM, Platt JL. Complement-mediated regulation of tissue factor activity in endothelium. J Exp Med 1995 182 : 1807 14.
13. van der Poll T, de Jong E, Levi M. Regulatory role of cytokines in disseminated intravascular coagulation. Semin Thromb Hemost 2001 27 : 639 51.
14. Moll T, Czyz M, Holzmuller H, et al. Regulation of the tissue factor promoter in endothelial cells. Binding of NF kappa B-, AP-1-, and Sp1-like transcription factors. J Biol Chem 1995 270 : 3849 57.
15. van der Poll T, Levi M, van Deventer SJ, et al. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 1994 83 : 446 51.
16. van der Poll T, Levi M, Hack CE, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994 179 : 1253 9.
17. Levi M, van der Poll T, ten Cate H, van Deventer SJ. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest 1997 27 : 3 9.
18. Neumann FJ, Ott I, Marx N, et al. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler Thromb Vasc Biol 1997 17 : 3399 405.
19. Schwager I, Jungi TW. Effect of human recombinant cytokines on the induction of macrophage procoagulant activity. Blood 1994 83 : 152 60.
20. Jansen PM, Boermeester MA, Fischer E, et al. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia. Blood 1995 86 : 1027 34.
21. van der Poll T, Levi M, Buller HR, et al. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med 1991 174 : 729 32.
22. Pajkrt D, van der Poll T, Levi M, et al. Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood 1997 89 : 2701 5.
23. Abraham E. Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol 2000 22 : 401 4.
24. Levi M, van der Poll T, ten Cate H, et al. Differential effects of anti-cytokine treatment on bronchoalveolar hemostasis in endotoxemic chimpanzees. Am J Respir Crit Care Med 1998 158 : 92 8.
25. Bastarache JA, Wang L, Geiser T, et al. The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax 2007 62 : 608 16.
26. Miller DL, Welty-Wolf K, Carraway MS, et al. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 2002 26 : 650 8.
27. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 1989 134 : 1087 97.
28. McGee MP, Rothberger H. Tissue factor in bronchoalveolar lavage fluids. Evidence for an alveolar macrophage source. Am Rev Respir Dis 1985 131 : 331 6.
29. Jesmin S, Gando S, Matsuda N, et al. Temporal changes in pulmonary expression of key procoagulant molecules in rabbits with endotoxin-induced acute lung injury: elevated expression levels of protease-activated receptors. Thromb Haemost 2004 92 : 966 79.
30. Maris NA, de Vos AF, Bresser P, et al. Activation of coagulation and inhibition of fibrinolysis in the lung after inhalation of lipopolysaccharide by healthy volunteers. Thromb Haemost 2005 93 : 1036 40.
31. Chapman HA, Stahl M, Allen CL, Yee R, Fair DS. Regulation of the procoagulant activity within the bronchoalveolar compartment of normal human lung. Am Rev Respir Dis 1988 137 : 1417 25.
32. Sitrin RG, Pan PM, Srikanth S, Todd RF III. Fibrinogen activates NF-kappa B transcription factors in mononuclear phagocytes. J Immunol 1998 161 : 1462 70.
33. Idell S, Peters J, James KK, Fair DS, Coalson JJ. Local abnormalities of coagulation and fibrinolytic pathways that promote alveolar fibrin deposition in the lungs of baboons with diffuse alveolar damage. J Clin Invest 1989 84 : 181 93.
34. Biemond BJ, Levi M, ten Cate H, et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clin Sci (Lond) 1995 88 : 587 94.
35. Idell S. Endothelium and disordered fibrin turnover in the injured lung: newly recognized pathways. Crit Care Med 2002 30 : S274 80.
36. Marshall BC, Sageser DS, Rao NV, Emi M, Hoidal JR. Alveolar epithelial cell plasminogen activator. Characterization and regulation. J Biol Chem 1990 265 : 8198 204.
37. Idell S. Extravascular coagulation and fibrin deposition in acute lung injury. New Horiz 1994 2 : 566 74.
38. Filippatos G, Tilak M, Pinillos H, Uhal BD. Regulation of apoptosis by angiotensin II in the heart and lungs (Review). Int J Mol Med 2001 7 : 273 80.
39. Chen CM, Chou HC, Wang LF, Lang YD. Captopril decreases plasminogen activator inhibitor-1 in rats with ventilator-induced lung injury. Crit Care Med 2008 36 : 1880 5.
40. Jiang JS, Wang LF, Chou HC, Chen CM. Angiotensin-converting enzyme inhibitor captopril attenuates ventilator-induced lung injury in rats. J Appl Physiol 2007 102 : 2098 103.
41. Wosten-van Asperen RM, Lutter R, Haitsma JJ, et al. ACE mediates ventilator-induced lung injury in rats via angiotensin II but not bradykinin. Eur Respir J 2008 31 : 363 71.
42. Yao S, Feng D, Wu Q, Li K, Wang L. Losartan attenuates ventilator-induced lung injury. J Surg Res 2008 145 : 25 32.
43. Barazzone C, Belin D, Piguet PF, Vassalli JD, Sappino AP. Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. J Clin Invest 1996 98 : 2666 73.
44. Eitzman DT, McCoy RD, Zheng X, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996 97 : 232 7.
45. Hasegawa N, Husari AW, Hart WT, Kandra TG, Raffin TA. Role of the coagulation system in ARDS. Chest 1994 105 : 268 77.
46. Chapman HA Jr., Bertozzi P, Reilly JJ Jr. Role of enzymes mediating thrombosis and thrombolysis in lung disease. Chest 1988 93 : 1256 63.
47. Chapman HA Jr., Stone OL. A fibrinolytic inhibitor of human alveolar macrophages. Induction with endotoxin. Am Rev Respir Dis 1985 132 : 569 75.
48. Suzuki K, Gabazza EC, Hayashi T, Kamada H, Adachi Y, Taguchi O. Protective role of activated protein C in lung and airway remodeling. Crit Care Med 2004 32 : S262 5.
49. Papadimitriou E, Manolopoulos VG, Hayman GT, et al. Thrombin modulates vectorial secretion of extracellular matrix proteins in cultured endothelial cells. Am J Physiol 1997 272 : C1112 22.
50. Perez RL, Ritzenthaler JD, Roman J. Transcriptional regulation of the interleukin-1beta promoter via fibrinogen engagement of the CD18 integrin receptor. Am J Respir Cell Mol Biol 1999 20 : 1059 66.
51. Seeger W, Stohr G, Wolf HR, Neuhof H. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol 1985 58 : 326 38.
52. Idell S, Koenig KB, Fair DS, Martin TR, McLarty J, Maunder RJ. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol 1991 261 : L240 8.
53. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006 32 (Suppl. 1 49 60.
54. Zheng X, Li W, Song Y, et al. Non-hematopoietic EPCR regulates the coagulation and inflammatory responses during endotoxemia. J Thromb Haemost 2007 5 : 1394 400.
55. Shimizu S, Gabazza EC, Taguchi O, et al. Activated protein C inhibits the expression of platelet-derived growth factor in the lung. Am J Respir Crit Care Med 2003 167 : 1416 26.
56. Yuda H, Adachi Y, Taguchi O, et al. Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood 2004 103 : 2196 204.
57. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000 407 : 258 64.
58. Levi M, van der Poll T, ten Cate H. Tissue factor in infection and severe inflammation. Semin Thromb Hemost 2006 32 : 33 9.
59. Ollivier V, Bentolila S, Chabbat J, Hakim J, de PD. Tissue factor-dependent vascular endothelial growth factor production by human fibroblasts in response to activated factor VII. Blood 1998 91 : 2698 703.
60. Kaner RJ, Ladetto JV, Singh R, Fukuda N, Matthay MA, Crystal RG. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol 2000 22 : 657 64.
61. Camerer E, Gjernes E, Wiiger M, Pringle S, Prydz H. Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem 2000 275 : 6580 5.
62. Abe K, Shoji M, Chen J, et al. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor. Proc Natl Acad Sci USA 1999 96 : 8663 8.
63. Cunningham MA, Romas P, Hutchinson P, Holdsworth SR, Tipping PG. Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory effects in macrophages. Blood 1999 94 : 3413 20.
64. Lorant DE, Topham MK, Whatley RE, et al. Inflammatory roles of P-selectin. J Clin Invest 1993 92 : 559 70.
65. Nicholson AC, Nachman RL, Altieri DC, et al. Effector cell protease receptor-1 is a vascular receptor for coagulation factor Xa. J Biol Chem 1996 271 : 28407 13.
66. Camerer E, Rottingen JA, Gjernes E, et al. Coagulation factors VIIa and Xa induce cell signaling leading to up-regulation of the egr-1 gene. J Biol Chem 1999 274 : 32225 33.
67. Fan J, Kapus A, Li YH, Rizoli S, Marshall JC, Rotstein OD. Priming for enhanced alveolar fibrin deposition after hemorrhagic shock: role of tumor necrosis factor. Am J Respir Cell Mol Biol 2000 22 : 412 21.
68. van der Poll T, Buller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990 322 : 1622 7.
69. Levi M, Schultz MJ, Rijneveld AW, van der Poll T. Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med 2003 31 : S238 42.
70. Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991 88 : 1346 53.
71. Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol 1988 4 : 93 126.
72. Gyetko MR, Sud S, Kendall T, Fuller JA, Newstead MW, Standiford TJ. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J Immunol 2000 165 : 1513 9.
73. Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, van der Poll T. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 2002 168 : 3507 11.
74. Abraham E, Gyetko MR, Kuhn K, et al. Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation. J Immunol 2003 170 : 5644 51.
75. Kwak SH, Mitra S, Bdeir K, et al. The kringle domain of urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation through interaction with [alpha]V[beta]3 integrins. J Leukoc Biol 2005 78 : 937 45.
76. Wang XQ, Bdeir K, Yarovoi S, Cines DB, Fang W, Abraham E. Involvement of the urokinase kringle domain in lipopolysaccharide-induced acute lung injury. J Immunol 2006 177 : 5550 7.
77. Carmeliet P, Collen D. Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb Res 1998 91 : 255 85.
78. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997 100 : 58 67.
79. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997 9 : 714 24.
80. Kjoller L, Kanse SM, Kirkegaard T, et al. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997 232 : 420 9.
81. Rijneveld AW, Florquin S, Bresser P, et al. Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 2003 102 : 934 9.
82. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 2006 116 : 3211 9.
83. Fuchs-Buder T, de Moerloose P, Ricou B, et al. Time course of procoagulant activity and D dimer in bronchoalveolar fluid of patients at risk for or with acute respiratory distress syndrome. Am J Respir Crit Care Med 1996 153 : 163 7.
84. Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003 285 : L20 8.
85. Gunther A, Mosavi P, Heinemann S, et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000 161 : 454 62.
86. Houldsworth S, Andrew PW, Mitchell TJ. Pneumolysin stimulates production of tumor necrosis factor alpha and interleukin-1 beta by human mononuclear phagocytes. Infect Immun 1994 62 : 1501 3.
87. Riesenfeld-Orn I, Wolpe S, Garcia-Bustos JF, Hoffmann MK, Tuomanen E. Production of interleukin-1 but not tumor necrosis factor by human monocytes stimulated with pneumococcal cell surface components. Infect Immun 1989 57 : 1890 3.
88. Simpson SQ, Singh R, Bice DE. Heat-killed pneumococci and pneumococcal capsular polysaccharides stimulate tumor necrosis factor-alpha production by murine macrophages. Am J Respir Cell Mol Biol 1994 10 : 284 9.
89. Mory-Rivier CF, Mohler J, Bedos JP, et al. Nuclear factor-kappaB activation in mouse lung lavage cells in response to Streptococcus pneumoniae pulmonary infection. Crit Care Med 2000 28 : 3249 56.
90. Geelen S, Bhattacharyya C, Tuomanen E. Induction of procoagulant activity on human endothelial cells by Streptococcus pneumoniae. Infect Immun 1992 60 : 4179 83.
91. Schultz MJ, Millo J, Levi M, et al. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004 59 : 130 5.
92. Rijneveld AW, Weijer S, Bresser P, et al. Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med 2006 34 : 1725 30.
93. Choi G, Schultz MJ, van Till JW, et al. Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection. Eur Respir J 2004 24 : 786 9.
94. El Solh AA, Schultz M. Decreased alveolar fibrinolysis in patients with ventilator-associated pneumonia: a species-specific event. Anesthesiology 2007 107 : 677.
95. Song Y, Lynch SV, Flanagan J, et al. Increased plasminogen activator inhibitor-1 concentrations in bronchoalveolar lavage fluids are associated with increased mortality in a cohort of patients with Pseudomonas aeruginosa. Anesthesiology 2007 106 : 252 61.
96. Yamamoto K, Loskutoff DJ. Extrahepatic expression and regulation of protein C in the mouse. Am J Pathol 1998 153 : 547 55.
97. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD. Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007 35 : 1821 8.
98. Yan SB, Dhainaut JF. Activated protein C versus protein C in severe sepsis. Crit Care Med 2001 29 : S69 74.
99. Sandset PM, Andersson TR. Coagulation inhibitor levels in pneumonia and stroke: changes due to consumption and acute phase reaction. J Intern Med 1989 225 : 311 6.
100. Bajaj MS, Kuppuswamy MN, Manepalli AN, Bajaj SP. Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. Thromb Haemost 1999 82 : 1047 52.
101. Bastarache JA, Wang L, Wang Z, Albertine KH, Matthay MA, Ware LB. Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. Am J Physiol Lung Cell Mol Physiol 2008 294 : L874 81.
102. Gando S, Kameue T, Matsuda N, et al. Imbalances between the levels of tissue factor and tissue factor pathway inhibitor in ARDS patients. Thromb Res 2003 109 : 119 24.
103. de Moerloose P, De Benedetti E, Nicod L, Vifian C, Reber G. Procoagulant activity in bronchoalveolar fluids: no relationship with tissue factor pathway inhibitor activity. Thromb Res 1992 65 : 507 18.
104. Sabharwal AK, Bajaj SP, Ameri A, et al. Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis. Am J Respir Crit Care Med 1995 151 : 758 67.
105. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 1996 88 : 881 6.
106. Iba T, Yagi Y, Kidokoro A, Fukunaga M, Fukunaga T. Increased plasma levels of soluble thrombomodulin in patients with sepsis and organ failure. Surg Today 1995 25 : 585 90.
107. Ware LB, Fang X, Matthay MA. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003 285 : L514 21.
108. Maruyama I, Bell CE, Majerus PW. Thrombomodulin is found on endothelium of arteries, veins, capillaries, and lymphatics, and on syncytiotrophoblast of human placenta. J Cell Biol 1985 101 : 363 71.
109. Ogawa H, Yonezawa S, Maruyama I, et al. Expression of thrombomodulin in squamous cell carcinoma of the lung: its relationship to lymph node metastasis and prognosis of the patients. Cancer Lett 2000 149 : 95 103.
110. Hofstra JJ, Juffermans NP, Schultz MJ, Zweers MM. Pulmonary coagulopathy as a new target in lung injury - a review of available pre-clinical models. Curr Med Chem 2008 15 : 588 95.
111. Murakami K, Okajima K, Uchiba M, et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997 272 : L197 202.
112. Yasui H, Gabazza EC, Tamaki S, et al. Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am J Respir Crit Care Med 2001 163 : 1660 8.
113. Choi G, Vlaar AP, Schouten M, et al. Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation. Eur Respir J 2007 30 : 423 8.
114. Choi G, Hofstra JJ, Roelofs JJ, et al. Recombinant human activated protein C inhibits local and systemic activation of coagulation without influencing inflammation during Pseudomonas aeruginosa pneumonia in rats. Crit Care Med 2007 35 : 1362 8.
115. Kotanidou A, Loutrari H, Papadomichelakis E, et al. Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice. Vascul Pharmacol 2006 45 : 134 40.
116. Slofstra SH, Groot AP, Maris NA, Reitsma PH, Cate HT, Spek CA. Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. Br J Pharmacol 2006 149 : 740 6.
117. van der Poll T, Levi M, Nick JA, Abraham E. Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med 2005 171 : 1125 8.
118. Nick JA, Coldren CD, Geraci MW, et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004 104 : 3878 85.
119. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001 86 : 51 6.
120. Robriquet L, Collet F, Tournoys A, et al. Intravenous administration of activated protein C in Pseudomonas-induced lung injury: impact on lung fluid balance and the inflammatory response. Respir Res 2006 7 : 41.
121. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001 344 : 699 709.
122. Vincent JL, Angus DC, Artigas A, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003 31 : 834 40.
123. Laterre PF, Garber G, Levy H, et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005 33 : 952 61.
124. Liu KD, Levitt J, Zhuo H, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008 178 : 618 23.
125. Enkhbaatar P, Okajima K, Murakami K, et al. Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation. Am J Respir Crit Care Med 2000 162 : 1752 9.
126. Opal SM, Palardy JE, Parejo NA, Creasey AA. The activity of tissue factor pathway inhibitor in experimental models of superantigen-induced shock and polymicrobial intra-abdominal sepsis. Crit Care Med 2001 29 : 13 7.
127. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Crit Care Med 2001 29 : 2081 9.
128. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 2003 290 : 238 47.
129. Wunderink RG, Poole L, Xie F, et al. Coagulation status and response to tifacogin in community-acquired pneumonia. Chest 2008 128 : 151S.
130. Oelschlager C, Romisch J, Staubitz A, et al. Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells. Blood 2002 99 : 4015 20.
131. Ostrovsky L, Woodman RC, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 1997 96 : 2302 10.
132. Duensing TD, Wing JS, van Putten JP. Sulfated polysaccharide-directed recruitment of mammalian host proteins: a novel strategy in microbial pathogenesis. Infect Immun 1999 67 : 4463 8.
133. Choi G, Hofstra JJ, Roelofs JJ, et al. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med 2008 36 : 204 10.
134. Abubakar K, Schmidt B, Monkman S, Webber C, deSA D, Roberts R. Heparin improves gas exchange during experimental acute lung injury in newborn piglets. Am J Respir Crit Care Med 1998 158 : 1620 5.
135. Enkhbaatar P, Cox RA, Traber LD, et al. Aerosolized anticoagulants ameliorate acute lung injury in sheep after exposure to burn and smoke inhalation. Crit Care Med 2007 35 : 2805 10.
136. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol 1996 270 : L921 30.
137. Kipnis E, Guery BP, Tournoys A, et al. Massive alveolar thrombin activation in Pseudomonas aeruginosa-induced acute lung injury. Shock 2004 21 : 444 51.
138. Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998 24 : 663 72.
139. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001 286 : 1869 78.
140. Esmon CT, Ding W, Yasuhiro K, et al. The protein C pathway: new insights. Thromb Haemost 1997 78 : 70 4.
141. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995 270 : 14477 84.
142. Myles T, Nishimura T, Yun TH, et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003 278 : 51059 67.
143. Van de Wouwer M, Conway EM. Novel functions of thrombomodulin in inflammation. Crit Care Med 2004 32 : S254 61.
144. Conway EM, Van de Wouwer M, Pollefeyt S, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappaB and mitogen-activated protein kinase pathways. J Exp Med 2002 196 : 565 77.
145. Uchiba M, Okajima K, Murakami K, Johno M, Okabe H, Takatsuki K. Recombinant thrombomodulin prevents endotoxin-induced lung injury in rats by inhibiting leukocyte activation. Am J Physiol 1996 271 : L470 5.
146. Uchiba M, Okajima K, Murakami K, Nawa K, Okabe H, Takatsuki K. Recombinant human soluble thrombomodulin reduces endotoxin-induced pulmonary vascular injury via protein C activation in rats. Thromb Haemost 1995 74 : 1265 70.
147. Rijneveld AW, Weijer S, Florquin S, et al. Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide. Blood 2004 103 : 1702 9.
148. Stringer KA, Bose SK, McCord JM. Antiinflammatory activity of tissue plasminogen activator in the carrageenan rat footpad model. Free Radic Biol Med 1997 22 : 985 8.
149. Stringer KA, Hybertson BM, Cho OJ, Cohen Z, Repine JE. Tissue plasminogen activator (tPA) inhibits interleukin-1 induced acute lung leak. Free Radic Biol Med 1998 25 : 184 8.
150. Renckens R, Roelofs JJ, Stegenga ME, et al. Transgenic tissue-type plasminogen activator expression improves host defense during Klebsiella pneumonia. J Thromb Haemost 2008 6 : 660 8.
151. Hardaway RM, Williams CH, Marvasti M, et al. Prevention of adult respiratory distress syndrome with plasminogen activator in pigs. Crit Care Med 1990 18 : 1413 8.
152. Sisson TH, Hanson KE, Subbotina N, Patwardhan A, Hattori N, Simon RH. Inducible lung-specific urokinase expression reduces fibrosis and mortality after lung injury in mice. Am J Physiol Lung Cell Mol Physiol 2002 283 : L1023 32.
153. Gunther A, Lubke N, Ermert M, et al. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 2003 168 : 1358 65.
154. Hart DA, Whidden P, Green F, Henkin J, Woods DE. Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model. Clin Invest Med 1994 17 : 69 76.
155. Hardaway RM, Harke H, Tyroch AH, Williams CH, Vazquez Y, Krause GF. Treatment of severe acute respiratory distress syndrome: a final report on a phase I study. Am Surg 2001 67 : 377 82.
156. Izuhara Y, Takahashi S, Nangaku M, et al. Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis. Arterioscler Thromb Vasc Biol 2008 28 : 672 7.